5 :: KDA, Korean Diabetes Association ::
string(8) "resource"
Subject    :    [2016 Jun;40(3)] Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus
Writer KDA
Date 2016-07-05 17:16:52 Hit 6,061
LINK URL http://e-dmj.org/DOIx.php?id=10.4093/dmj.2016.40.3.240 (Click 238)
Diabetes Metab J. 2016 Jun;40(3):240-247. English.
Published online Apr 05, 2016.  http://dx.doi.org/10.4093/dmj.2016.40.3.240 
Copyright © 2016 Korean Diabetes Association
   
Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus
Sejeong Park,1,* So Young Park,2,* Yu Jin Kim,2 Soo Min Hong,1, Suk Chon,1,3 Seungjoon Oh,1,3 Jeong-taek Woo,1,3 Sung-Woon Kim,1,3 Young Seol Kim,4 and Sang Youl Rhee1,3
1Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
2Department of Endocrinology and Metabolism, College of Medicine, Kyung Hee University, Seoul, Korea.
3Research Institute of Endocrinology, Kyung Hee University, Seoul, Korea.
4Department of Internal Medicine, Chung Hospital, Seongnam, Korea.

Corresponding author: Sang Youl Rhee. Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea. Email:bard95@hanmail.net

 

*Sejeong Park and So Young Park contributed equally to this study as first authors.

 

Current affiliation: Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
 
Received July 29, 2015; Accepted October 05, 2015.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Background

Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM.

Methods

Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms.

Results

A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (PP

Conclusion

Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.

   
Keywords:
Diabetes mellitus, type 2; Gastrointestinal diseases; Rebamipide
 

Articles - Reviews in DMJ
No. Subject Date Hit ↑
Notice : [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iro... 2019-10-10 842
Notice : [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrom... 2019-10-10 849
Notice : [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabo... 2019-10-10 829
Notice : [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Aci... 2019-10-10 837
Notice : [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in ... 2019-10-10 826
Notice : [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal o... 2019-10-10 795
Notice : [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes Mellitus in A Chinese Population: A Nested Case-Control Study [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes ... 2019-10-10 778
Notice : [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011) [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuri... 2019-10-10 809
Notice : [2019 Aug;43(4)] Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies [2019 Aug;43(4)] Association between Serum Selenium Level and the Pr... 2019-10-10 789
Notice : [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Gl... 2019-10-10 781
Notice : [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with... 2019-10-10 796
Notice : [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovasc... 2019-10-10 780
Notice : [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabet... 2019-10-10 807
Notice : [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes ... 2019-10-10 790
Notice : [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Ob... 2019-06-28 2,150
Notice : [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood... 2019-06-28 2,308
Notice : [2019 June;43(3)]  Oral Glucose Tolerance Testing Allows Better Prediction of Diabetes in Women with a History of Gestational Diabetes Mellitus [2019 June;43(3)] Oral Glucose Tolerance Testing Allows Better Pred... 2019-06-28 2,132
Notice : [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A ... 2019-06-28 2,166
Notice : [2019 June;43(3)]  Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis [2019 June;43(3)] Effectiveness of Exercise Intervention in Reducin... 2019-06-28 2,093
Notice : [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Di... 2019-06-28 2,536
Notice : [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in... 2019-06-28 2,068
Notice : [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: Fro... 2019-06-28 2,075
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 2,325
252 [2015 Oct;39(5)] Relationship between Biological Markers, Metabolic ... 2015-12-08 6,367
251 [2015 Oct;39(5)] Serum Total Bilirubin Levels Provide Additive Risk ... 2015-12-08 6,360
250 [2015 Dec;39(6)] Insulin Initiation in Insulin-Naïve Korean Type 2... 2016-01-07 6,321
249 [2015 Dec;39(6)] The Usefulness of the Glycosylated Hemoglobin Level... 2016-01-07 6,281
248 [2015 Oct;39(5)] Increased Epicardial Adipose Tissue Thickness in Ty... 2015-12-08 6,173
247 [2016 Jun;40(3)] Renoprotective Effect of Gemigliptin, a Dipeptidyl ... 2016-07-05 6,135
246 [2015 Oct;39(5)] Dipeptidyl Peptidase 4 Inhibitors and the Risk of C... 2015-12-08 6,120
245 [2015 Oct;39(5)] Interaction between Glucose and Lipid Metabolism: M... 2015-12-08 6,113
244 [2016 Jun;40(3)] Effects of Rebamipide on Gastrointestinal Symptoms ... 2016-07-05 6,061
243 [2015 Dec;39(6)] Morphologic Changes in Autonomic Nerves in Diabetic... 2016-01-07 6,052

목록

Gets the previous 5 pages.   Go to previous page.  1   2   3   4   [5]     Go to next page. Gets the next  5 pages.